Dyax Corp. (DYAX) said that it has received the FDA approval for Kalbitor to treat acute attacks of hereditary angioedema or HAE in patients 16 years of age and older.
HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling, which can occur in the abdomen, face, hands, feet and airway.
Kalbitor, which is discovered and developed by Dyax, is the first subcutaneous HAE treatment approved in the U.S.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.